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ABSTRAK 
 
Latar belakang dan Tujuan: 
Peningkatan minat dalam penggabungan propofol-ketamine sebagai campuran untuk 
sedasi dan pembiusan telah membawa kepada kajian untuk mendapatkan campuran 
yang sesuai. Kajian ini dilakukan untuk membandingkan kesan dari dua campuran 
propofol-ketamine yang berbeza dari sudut kestabilan hemodinamik, keadaan yang 
sesuai untuk kemasukan Proseal LMA dan kadar apnoea selepas induksi. 
 
Bentuk kajian: 
Kajian random di satu pusat, melibatkan dua kumpulan dilakukan di Hospital 
Universiti Sains Malaysia di antara June 2014 dan October 2014. 
 
Pesakit dan kaedah: 
Seramai 88 orang peserta telah direkrut dan dibahagikan secara rawak kepada dua 
kumpulan menggunakan „blok‟ rawak. Satu kumpulan pesakit diberikan propofol 
ketamine dengan nisbah 1:1, manakala satu lagi kumpulan menggunakan propofol-
ketamine nisbah 1:0.5. Rekod hemodinamik dilakukan pada waktu permulaan, 1 
minit, 5 minit and 10 minit selepas induksi. 
 
 
 
ix 
 
Proseal dimasukkan untuk setiap pesakit selepas induksi. Markah skor LMA dan 
skor „apnoea‟ direkodkan.  
 
Keputusan 
 
 
 
Berdasarkan perbandingan dalam kumpulan, kedua-dua kumpulan propofol-
ketamine menunjukkan perubahan yang signifikan dari aspek statistic dalam SBP, 
DBP, MAP dan HR hampir pada setiap masa yang direkodkan. 
Walaubagaimanapun, perbandingan di antara kedua-dua kumpulan tidak 
menunjukkan perubahan yang signifikan dari aspek statistik 
Peratusan median untuk saturasi oksigen dan markah kemasukan Proseal LMA 
adalah hampir sama bagi kedua-dua kumpulan. Tidak ada perbezaan yang signifikan 
antara kedua-dua kumpulan dalam min Proseal LMA skor. Begitu juga dalam faktor 
yang berkaitan dengan markah proseal LMA, tidak ada perbezaan yang signifikan. 
Kumpulan propofol / Ketamine nisbah 1:1 mempunyai peratusan ‘prolonged apnoea’ 
yang lebih tinggi dari kumpulan propofol/ketamine 1:0.5 (90.9% vs 13.6%; 
p<0.001). terdapat dua faktor berkaitan dengan skor ‘apnoea’ yang signifikan iaitu 
BMI (OR disesuaikan 1.148, 95% CI 0.964, 1.583) dan kumpulan intervensi (OR 
disesuaikan 49.765, 95% CI 12.789, 193.649).  
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Kesimpulan:  
 
Campuran propofol/ketamine nisbah 1:0.5 adalah lebih baik dari propofol/ketamine 
nisbah 1:1 kerana ia kurang assosiasi dengan kadar ‘apnoea’. Walaubagaimanapun, 
kesan hemodinamik adalah stabil dan agak sama dalam kedua-dua kumpulan. 
  
Keywords: Propofol-ketamine, fentanyl, Proseal 
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 ABSTRACT 
 
Background and Aims: 
 
 
The renewed interest in combination of propofol-ketamine as a mixture for sedation 
and anaesthesia had leaded us to search for a suitable mixture to be used for 
induction of anaesthesia. This study was conducted to compare the effects of two 
different mixture of propofol–ketamine on haemodynamic stability, adequate 
condition for Proseal LMA insertion and occurrence of apnoea after induction. 
 
Settings and Design: 
 
A randomized double-blinded, controlled trial was conducted in Hospital Universiti 
Sains Malaysia between June 2014 and October 2014. 
 
 
Patients and Methods: 
 
A total of 88 patients were recruited and randomized into two groups using block 
randomization. One group of patients was given propofol-ketamine with 1:1 ratio; 
whereas another group was given propofol-ketamine 1:0.5 ratio. Haemodynamic 
monitoring was measured at baseline, 1 minute, 5 minute and 10 minutes after 
induction.  Proseal was inserted in each patient after successful induction. LMA 
scoring and apnoea scoring were recorded.  
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Results: 
 
In regard to within-intervention-group-effect comparisons, both 1:0.5 and 1:1 
propofol / ketamine ratio groups showed statistically significant changes in SBP, 
DBP, MAP and HR  nearly across all time points. However, regarding between-and-
within-intervention-group comparisons (i.e. comparison of SBP, DBP, MAP and HR 
between intervention groups across time points), there were no significant marginal 
mean differences noted between both propofol / ketamine ratio groups across time. 
The medians percentage of oxygen saturation was exactly the same for both groups 
of intervention. There was no significant difference in mean Proseal LMA score 
between the two groups. There were also no significant predictors between 
associated with Proseal LMA score. The 1:1 propofol / ketamine ratio group has 
higher percentage of prolonged apnoea than 1:0.5 propofol/ketamine group (90.9% 
vs 13.6; p < 0.001).  There were two significant predictors for apnoea score which 
were BMI (adjusted OR 1.148, 95% CI 0.964, 1.583) and intervention group 
(adjusted OR 49.765, 95% CI 12.789, 193.649)  
 
Conclusions: 
 
Propofol/ketamine mixture with 1:0.5 ratio was better than propofol/ketamine 1:1 
because it caused lesser association to apnoea occurrence. However the 
haemodynamic response were stable and comparable in both groups.  
 
Keywords: Propofol-ketamine, fentanyl, Proseal 
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CHAPTER 1 INTRODUCTION 
 
 Propofol as an induction agent produces loss of consciousness by facilitation of 
inhibitory neurotransmission mediated by GABA. Its main strong points are its quick 
induction and recovery,  with antiemetic effects, an anticonvulsant effects and an amnestic 
agent (Short and Aun, 1991). Although propofol is exceptionally effective and potent, its use 
is limited by   high incidence of hypotension and respiratory depression (Hug et al., 1993).  
Ketamine is an anaesthetic agent that acts by stimulating the sympathetic nervous 
system and increasing blood pressure along with increasing the heart rate. Ketamine as 
anaesthetic agent provides powerful amnesia and analgesia, and it able to maintain airway 
reflexes and spontaneous respiration (Warncke et al., 1997).  
Improved haemodynamic stability after induction has been shown with the usage of 
propofol-ketamine, commonly referred to as „ketofol‟ (Ghatak et al., 2012). The anaesthetic 
agent ketamine stimulates the sympathetic nervous system and increases blood pressure 
along with increasing the heart rate.  It was observed that addition of ketamine reduced 
consumption of propofol and opioids and ensured better respiratory stability in patients.  
 There are numerous ways been done to combine propofol and ketamine. Many studies 
compared different concentration of propofol-ketamine. Badrinath et al. (2000) reported that 
ratio of 1:5 ketofol with local anaesthesia provides good analgesia and sedation for breast 
biopsy procedure. They reported that combination of propofol and ketamine (5:1) provides 
effective sedation/analgesia during monitored anaesthesia care. A study was performed 
using a mixture of the 1:1 compared with 1:2 ketamine-propofol. Nausea, hallucination and 
recovery time were observed more in 1:1 ratio solution. Andolfatto and Willman (2010) 
reported 1:1 ratio of ketofol is highly effective in paediatric emergency procedures. 
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The role of fentanyl in improving PLMA insertion prior to propofol has been 
studied. It enhances the insertion conditions with success rate up to 85-95% (Cheam and 
Chui, 2000). The ProSeal Laryngeal Mask Airway (PLMA) has significant advantage over 
Classic LMA in that it protects the lungs from aspiration and the stomach from gastric 
insufflations by facilitating passage of a gastric tube and monitoring devices into the 
ooesophagus. Its insertion technique is the same as  the Classic or Intubating LMA 
(Brimacombe and Keller, 2000). Insertion of the PLMA after induction of anaesthesia 
requires adequate depth of anaesthesia for suppression of airway reflexes. 
The primary goal of this study is to determine a better mixture of ketofol for general 
anaesthesia induction for Proseal LMA insertion in terms of haemodynamic stability, 
easiness of insertion and percentage of occurence of apnoea. No study has been done to 
compare the different concentration of ketamine-propofol (ketofol) on LMA Proseal 
insertion with the effect of fentanyl pretreatment in both group.   
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CHAPTER 2 LITERATURE REVIEW 
 
2.1 PROPOFOL 
 
2.11 CHEMISTRY AND FORMULATIONS 
 
 Propofol was introduced in 1970s as 2,6-diisopropofol. At first, it was prepared with 
Cremophor EL because of its insolubility. However, reports of anaphylcatoid reactions 
emerged resulting in production of propofol in emulsion. Currently, propofol is used for 
induction and maintenance of anaesthesia and for sedation. Now, propofol is the most 
popular IV anaesthetic used by clinicians.   
 Propofol is classified as alkylphenols, which is oil at room. Propofol is produced for 
IV administration as a 1% (10 mg/mL) emulsion in 10% soybean oil, 2.25% glycerol, and 
1.2% purified egg phosphatide. This formulation is slightly viscous, with milky white 
substance and has a pH of 7. It is insoluble in aqueous solutions. In some countries, a 
formulation in which the emulsion contains a mixture of medium-chain and long-chain 
triglycerides has been used. A 2% formulation has also been developed. Propofol is stable at 
room temperature and are not light sensitive. 
 
2.12 PHARMACOKINETICS 
 
 Propofol is a lipophilic weak acid. Two-compartment and three-compartment models 
have been used to described the pharmacokinetics of propofol. Blood propofol levels will 
decrease rapidly after a single bolus injection, due to redistribution and elimination. The 
initial distribution half-life of propofol is 2 to 8 minutes and slow distribution half-lives is 30 
to 70 minutes and an elimination half-life of 4 to 23.5 hours. The long elimination half-life 
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points toward a deep compartment with limited perfusion, which cause a slow return of 
propofol back to the central compartment.  
 
 
FIGURE 2-1 PHARMACOKINETIC VARIABLES FOR COMMONLY USED 
INTRAVENOUS ANAESTHETICS 
 
 The context-sensitive half-time for infusion of propofol up to 8 hours is less than 40 
minutes (Hughes et al., 1992). The recovery from propofol remains rapid even after 
prolonged infusions because propofol concentration usually just need to be less than 50% for 
awakening after anaesthesia or sedation. The volume of distribution of the central 
compartment is from 20 to 40 L, and the volume of distribution at steady state has been 
calculated as 150 to 700 L. The clearance of propofol is greater than hepatic blood flow, 
which is at 1.5 to 2.2 L/min. This suggests that extrahepatic metabolism has played a role in 
propofol clearance.  
 Propofol is able to decrease hepatic blood flow and reduce its own clearance. Changes 
in cardiac output may influence propofol concentrations as shown after a bolus dose and 
during constant infusion. Propofol concentrations in plasma decrease by increasing cardiac 
output, and increases when cardiac output decreases.  
 In general children have about 50 percent larger central compartment volume than 
adult patient with a more rapid clearance. Children are usually divided between those older 
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than 3 years, and younger than 3 years old. In the latter group, they have larger central 
compartment and systemic clearance values than in adults or older children (Kataria et al., 
1994).   
 
2.13 METABOLISM 
 
 Propofol metabolism via conjugation results in production of glucuronide and sulfates 
and will be excreted by the kidneys. Most of the propofol will be metabolized, with 2% is 
excreted in faeces and less than 1% is excreted in urine. As mentioned above, it has been 
suggested that propofol clearance exceeds hepatic blood flow and extrahepatic metabolism 
has been recommended. These extrahepatic metabolism include renal and lung system.  
 
 
FIGURE 2-2 APPARENT VOLUME OF DISTRIBUTION AT STEADY 
STATE 
 
2.14 PHARMACODYNAMICS 
 
2.141 CENTRAL NERVOUS SYSTEM 
 
 Propofol exerts its effect in CNS by binding to the ß-subunit of GABAA receptor 
hence increasing aminobutyric acid (GABA)–induced chloride current through it. Propofol 
will modulate GABAA receptors in the hippocampus to stop acetylcholine release in the 
hippocampus and prefrontal cortex (Kushikata et al., 2002).  
 Another mechanism by which propofol may contribute to the drug's hypnotic effects 
6 
 
is by inhibition of the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor. This 
will occur through its effect on sodium channel gating. In spinal cord propofol cause a direct 
depressant effect on its neurons. Two notable side effects of propofol are its antiemetic 
effect and a sense in patients.  
 Induction dose is influenced by patient‟s age with the largest at ages younger than 2 
years old. After 2 years old, induction dose decreasing with increasing age (Aun et al., 
1992). At lower doses, sedation and amnesia may be provided by propofol. A peak effect of 
90 to 100 seconds has been shown for the onset of hypnosis after a dose of 2.5 mg/kg. For 
loss of consciousness, the median effective dose (ED50) of propofol is 1 to 1.5 mg/kg after a 
bolus. Five to 10 minutes of hypnosis has been witnessed after 2 to 2.5 mg/kg of propofol, 
and this duration of hypnosis is dose-dependent.  
 High infusion rates of propofol could produce burst suppression in EEG (Reddy et al., 
1992). After 2.5 mg/kg of propofol followed by an infusion EEG shows an initial increase in 
alpha rhythm followed by a change to gamma and theta frequency. In BIS, propofol shows a 
concentration-dependent decrease in its level. 50% and 95% of patients unable to respond to 
a verbal command at BIS of 63 and 51. At a BIS value of 77, 95% of patients shows lack of 
recall (Glass et al., 1997).  
 Seizures have been reported after propofol administration, as the effect of propofol on 
EEG activity is controversial.  The seizure occurs usually on induction or recovery from 
anaesthesia and occasionally in the postoperative period. Propofol produces a direct 
anticonvulsant effect and it is dose-dependent.  
 
2.142 CARDIOVASCULAR 
 
 Propofol reduces systemic vascular resistance, cardiac contractility, and preload. 
Patients with impaired ventricular function poorly tolerate significant reductions in cardiac 
output as a result of decreases in ventricular filling pressures and contractility. Heart rate 
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increases secondary to activation of baroreceptor-mediated compensatory mechanisms in 
response to the reduction in cardiac output and systemic vascular resistance 
Propofol produces a dose-dependent decrease in blood pressure that is significantly 
greater than that produced by thiopental; the effect is explained by vasodilation and mild 
depression of myocardial contractility. Propofol appears to blunt the baroreceptor reflex or is 
directly vagotonic. As with thiopental, propofol should be used with caution in patients at 
risk for or intolerant of decreases in blood pressure. Propofol result in decrease in arterial 
blood pressure during induction of anaesthesia. Systolic blood pressure and diastolic blood 
pressure reduces from  25% to 40% and lead to a reduction of  cardiac output, cardiac index 
and stroke volume index and left ventricular stroke work.  
 Systemic blood pressure decrease after administration of propofol due to vasodilation 
and direct myocardial depressant effects of propofol. At concentrations more than 10 μg/mL  
the inotropic effect is abolished, and the lusitropic (relaxation) effect of ß stimulation is 
increased. The vasodilatory effect of propofol is dose-dependent and contributed by direct 
effect on intracellular smooth muscle calcium mobilization, reduction in sympathetic 
activity, reduction in angiotensin II–elicited calcium entry and inhibition of prostacyclin 
synthesis in endothelial cells. 
 Propofol may reduce the tachycardic response to hypotension by inhibiting the 
baroreflex, and result in insignificant change of heart rate. It also has minimal effect on 
sinoatrial node function or on normal atrioventricular and accessory pathway conduction. 
The heart rate response to atropine is also reduced by propofol. This is shown in a study 
where propofol infusion with concentration of 10 mg/kg/hr which result in cumulative dose 
of atropine of 30 μg/kg increased heart rate greater than 20 beats/min in only 20% of 
subjects compared with 100% in the absence of propofol. Mixture of propofol and 0.5mg/kg 
of ketamine could prevent decreases in haemodynamics after induction of anaesthesia with 
propofol. 
 Arterial systolic blood pressure also is decreased to 30% less than baseline level prior 
to induction during maintenance. After a bolus dose of propofol, peak plasma concentrations 
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are considerably higher than the concentrations seen with a continuous infusion.  
 
2.143 RESPIRATORY SYSTEM 
 
 An induction dose of propofol results in 30% incidence of apnoea. The incidence and 
duration of apnoea depend on dose, premedication and speed of injection of propofol. The 
apnoea may occur more than 30 seconds and may increase by contribution of premedication 
or opiate. The apnoea usually preceded by significant decrease of tidal volume and 
tachypnoea. Decrease in tidal volume up to 40%, with an increase in respiratory frequency 
up to 20% may occur during maintenance of propofol infusion. The response to carbon 
dioxide also is affected during propofol infusion. A 58% decrease in the slope of the carbon 
dioxide–response curve may occur at 100 μg/kg/min infusion. By increasing the infusion 
rate to twice its level leads to minimal decrease in carbon dioxide responsiveness. 
 Propofol influence carotid body chemoreceptors to reduce the ventilatory response to 
hypoxia in the range of 50 to 120 μg/kg/min. In patients with chronic obstructive pulmonary 
disease, propofol may cause bronchodilation. It reduces vagal and methacholine- induced 
bronchoconstriction and may also modulates muscarinic receptors. Propofol also may 
improve patients lung pathology as shown in animal model where propofol with 
concentration of 10 mg/kg/hr significantly reduced free radical mediated and 
cyclooxygenase catalyzed lipid peroxidation. This may help patients with adult respiratory 
distress syndrome. However these benefits are yet to confirmed in humans.  
  
2.144 OTHER EFFECTS 
 
 Reports of anaphylactoid reactions to the propofol have emerged. A large number of 
these cases had a previous history of allergic responses. Therefore propofol should be used 
carefully in patients with known drug allergies.  
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Its antiemetic activity is effective at low doses as shown in study where a bolus dose of 10 
mg has been used to treat postoperative nausea. A propofol infusion of 10 to 20 mg loading 
dose followed by 10 μg/kg/min can achieve median concentration of 343 ng/mL that is 
linked to its antiemetic effect.  
Propofol also been shown to be effective to treat cholestatic pruritus and may be as good as 
naloxone in treating pruritus induced by spinal opiates. However, this result has not been 
confirmed in other studies. 
 Measures such as aseptic technique must still be adhered during propofol infusion. 
The intralipid that acts as the solvent for propofol may act as an excellent culture medium. 
To prevent the bacterial growth, propofol has been added with preservative Disodium 
edetate or metabisulfite. 
 Pancreatitis has been associated with the administration of propofol which may be 
associated with hypertriglyceridaemia. Induction of anaesthesia with propofol is associated 
with several side effects, including pain on injection, myoclonus, apnoea, hypotension, and, 
rarely, thrombophlebitis of the vein into which propofol is injected.  
 Higher incidence of prolonged apnoea has been observed with propofol than other 
anaesthetic agent such as thiopental. Combination with opiate may increase the apnoea 
duration. Hypotension is usually observed during anaesthetic induction, and this could be 
worsened by addition of opioids. Haemodynamic changes such as MAP, heart rate, and 
systemic vascular resistance are less affected by laryngoscopy and endotracheal intubation 
when propofol is used, compared to thiopental. 
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2.15 USES 
 
2.151 INDUCTION AND MAINTENANCE OF ANAESTHESIA 
 
 The main indication for Propofol is for the induction and maintenance of anaesthesia 
at dose of 1 to 2.5 mg/kg. The induction dose can be markedly reduced by addition of opiate 
or a benzodiazepine as a premedication. Older and sicker patients may need lower dose of 
induction because the hypotension effect is more significant. These patients may need 
cautious loading with fluid prior to induction to reduce the severity of hypotension.
 Propofol result in faster recovery and an earlier return of psychomotor function when 
used for short procedure compared to other anaesthetic agent. Desflurane produce recovery 
slightly faster than propofol. In a procedure, propofol maintenance can be given via propofol 
infusion or intermittent boluses of 10 to 40 mg is needed every few minutes.  
 There are a few ways to use propofol as an infusion. Combination of propofol with 
other drugs such as of opiates, midazolam, clonidine, or ketamine may reduce its required 
dose. Opioids will reduce the opioid also affects the time from termination of drug to 
awakening and recovery.  
 After a satisfactory induction dose, a bolus of 10 to 40 mg is needed every few 
minutes to maintain anaesthesia. Because these doses need to be given frequently, it is more 
suitable to administer propofol as a continuous infusion. The usual dosage for propofol for 
induction of general anaesthesia is 1-2.5 mg/kg IV. For maintenance of anaesthesia 50-150 
μg/kg/min IV combined with an opiate and the range of blood concentration of propofol for 
maintenance of anaesthesia are 2.5 to 4.5 μg/mL. Propofol pharmacokinetics has allowed us 
to use propofol as a continuous infusion for the maintenance of anaesthesia.  
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2.152 SEDATION 
 
 Propofol has been used for sedation in ICU because it can be easily titrated to a 
desired level of sedation and provide a fast recovery after infusion is completed. One study 
showed patients regain consciousness within 10 minutes after being sedated in the ICU for 4 
days with propofol. The rate of recovery and the decrease in plasma concentration were 
similar at 24 hours and at 96 hours, when the infusion was discontinued. 
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2.2 KETAMINE 
 
2.21 CHEMISTRYAND FORMULATIONS 
 
Ketamine is a type of phencyclidine, water soluble but is 5 to 10 times more 
lipophilic than thiopental. It was first introduced into clinical anaesthesia in 1966. Compared 
to other anaesthetic drugs it has a significant analgesic effect. Ketamine also does not cause 
impair cardiovascular and respiratory systems. There are of two stereoisomers, S(+) and R(-) 
of ketamine. The S(+) is more powerful compared to R (-) counterpart. Ketamine is also 
used in chronic pain states, potential neuroprotective effects, total IV anaesthesia and its 
effects on hyperalgesia and opiate tolerance.  
Ketamine is partially water soluble with molecular weight of 238 kD. It is in a white 
crystalline salt form with a pKa of 7.5.  
 
 
 
 
FIGURE 2-3 STEREOISOMERS OF KETAMINE AS IT IS FORMULATED 
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2.22 PHARMACOKINETICS AND METABOLISM 
 
The onset and duration of an induction dose of ketamine are determined by the same 
distribution/redistribution mechanism for all the other parenteral anaesthetics. Ketamine is 
hepatically metabolized to norketamine, which has reduced CNS activity; norketamine is 
further metabolized and excreted in urine and bile. Ketamine has a large volume of 
distribution and rapid clearance that make it suitable for continuous infusion without the 
drastic lengthening in duration of action seen with thiopental (Table 13–2 and Figure 13–2). 
 Ketamine has large volume of distribution of 3 L/kg which is reflected by its high 
lipid solubility. Ketamine clearance is high at 890 to 1227 mL/min, which result in short 
elimination half-life of 2 to 3 hours. Any changes in liver blood flow affect ketamine 
clearance because its mean total body clearance at 1.4 L/min is about equal to liver blood 
flow. 
 However there are differences in the pharmacokinetics of the two isomers. S(+) 
ketamine has a larger elimination clearance and larger volume of distribution than R (-) 
ketamine.. The S(+) enantiomer also seems to be more potent in suppressing the EEG than 
either R(-) or the racemic mixture. 
 Ketamine can be given via an intranasal spray or by oral routes, but they are subject to 
significant first-pass metabolism. The bioavailability via oral administration is 20% to 30%, 
and via the intranasal route is approximately 40% to 50%. 
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FIGURE 2-4  SIMULATED TIME COURSE OF PLASMA LEVELS OF 
KETAMINE  
 
After an induction dose of 2mg/kg, plasma levels required for hypnosis and amnesia during 
surgery are 0.7 to 2.2mcg/ml, with awakening usually occurring at levels less than 
0.5mcg/ml. Ketamine is metabolized by n-demethylation to form norketamine by hepatic 
microsomal enzymes. Norketamine is then hydroxylated to hydroxynorketamine and both 
metabolites will be conjugated to water-soluble glucuronide derivatives. These products will 
be excreted in urine. Norketamine may prolong the analgesic effect of the parent drug 
although some study showed it has less activity than ketamine. 
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2.23 PHARMACODYNAMICS 
 
2.231 NERVOUS SYSTEM 
 
 Ketamine produces dissociative anaesthesia where patients appear to be in a cataleptic 
state. This has been described as profound analgesia, where patients keep their eyes open 
and maintain many reflexes. Patients could not recall surgery but amnesia effect will be 
better with benzodiazepines. The unconsciousness and analgesic effect is dose-dependent.  
 With a pKa of 7.5, and high lipid solubility, the onset of action starts within 30 to 60 
seconds of administration as it can cross the blood-brain barrier fast. The peak effect occurs 
in about 1 minute. Minimum concentrations for general anaesthesia are 0.6 to 2 μg/mL 
plasma concentration with interindividual variability. Typically, a general anaesthetic dose 
(2 mg/kg) will last for 10 to 15 minutes, and patients will regain full orientation within 15 to 
30 minutes. 
 After bolus of ketamine, lacrimation and salivation will occur, pupils will dilate, and 
nystagmus may be observed. Purposeless movements of the legs, arms and trunk may be 
noted as well. Larger doses will result in longer anaesthesia and combination with other 
anaesthetics may prolong the time of emergence. Short duration of ketamine is due to its 
redistribution from the brain and blood to the other tissues in the body. The effect will last 
until drug redistributes from the well-perfused to the less well-perfused tissues.   
 The S(+) enantiomer result in more rapid recovery than the racemic mixture due 
(Kharasch and Labroo, 1992) to the 10% faster hepatic biotransformation. If the S(+) 
enantiomer is combined with a benzodiazepine result showed no different in terms of 
awareness at 30 minutes, but it was considerably better at 120 minutes than the racemic 
mixture.  
 Ketamine provides effective postoperative analgesia at significantly lower blood 
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levels than anaesthetic doses. Pain thresholds are elevated at plasma ketamine concentration 
more than 0.1 μg/mL. The analgesic effect can occur subanaesthetic doses.  Ketamine acts to 
inhibit nociceptive central hypersensitization and it is able to reduce acute tolerance after 
opiate administration 
 Ketamine act primarily at the thalamoneocortical projection system. The drug will 
depresses neuronal function in parts of the cortex and thalamus while at the same time it will 
stimulate parts of the limbic system. This process creates what is termed a functional 
disorganization of nonspecific pathways in midbrain and thalamic areas 
 Ketamine may also occupies opiate receptors in the brain and spinal cord and give its 
analgesic property, especially S(+) enantiomer which has been shown to have some opioid 
μ-receptor. Ketamine also interact with NMDA which contribute to its anaesthetic and 
analgesic effect.  
 Ketamine results in CNS excitations, increases cerebral metabolism, CBF, and ICP. 
The CNS effect is reflected in generalized EEG development of theta wave activity and by 
petit mal seizure–like activity in the hippocampus. Overall, the ICP will increase secondary 
to increase in CBF and the generalized increase in sympathetic nervous system response. 
Ketamine preserves cerebrovascular responsiveness to carbon dioxide. Animal models 
showed ketamine reduces necrosis and improves neurologic outcome. It is suggested that 
ketamine mediate the reduction of necrotic cell death and involved in antiapoptotic 
mechanisms.  
 However in study with younger animals, ketamine accentuate apoptosis in the 
newborn brain of animals, similar with other anaesthetics either at high relative doses or 
with prolonged exposure and this create controversy over the use of ketamine in neonates. 
The spinal cord analgesic effect of ketamine is postulated to be due to inhibition of dorsal 
horn wide dynamic range neuronal activity. Although some drugs have been used to 
antagonize ketamine, no specific receptor antagonist is yet known that reverses all the CNS 
effects of ketamine. 
 Ketamine produces emergence reactions, which are described as vivid dreaming, 
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sense of floating out of body, and illusions which vary in severity. Excitement, confusion, 
euphoria, and fear are associated with dreaming and illusion. The incidence ranges from 3% 
(White et al., 1982) to 100% and about 10% to 30% of adult patients. These emergence 
reactions may be due to ketamine-induced depression of auditory and visual relay nuclei, 
leading to misperception or misinterpretation of auditory and visual stimuli. Typically it 
occurs in the first hour of emergence and usually abate within 1 to several hours. 
 The incidence of emergence reactions is low in paediatric patients. Certain personality 
types such as individuals who commonly dream at home or patients who score high in 
psychotism on the Eysenck Personality Inventory are more likely to develop emergence 
reactions. In general the emergence reactions are influenced by age, dose, gender, 
psychological susceptibility, and concurrent drugs. The most effective drug to suppress these 
reactions is the benzodiazepines.  
 
2.232 CARDIOVASCULAR SYSTEM 
 
 Ketamine stimulates the cardiovascular system by increasing in blood pressure, heart 
rate, and cardiac output. This is in contrast with other anaesthetic induction drugs which 
either cause no change in haemodynamic variables or produce vasodilation with cardiac 
depression. As a result of these stimulations, there is an increased work and myocardial 
oxygen consumption of the heart. However the haemodynamic changes are not dose 
dependent. Some author stated that there is no haemodynamic difference between IV 
administration of 0.5 mg/kg and 1.5 mg/kg. The haemodynamic change after ketamine 
induction is similar between healthy patients and in patients with heart diseases. Patients 
with elevated pulmonary artery pressure may have more significant increase in pulmonary 
than systemic vascular resistance. However, no considerable changes were noted in shunt 
directions or fraction or systemic oxygenation in patients with congenital heart disease.  
 Ketamine may reduce baroreceptor function via an effect on NMDA receptors in the 
18 
 
nucleus tractus solitaries. Ketamine also causes the sympathoneuronal release of 
noradrenaline, which can be detected in venous blood 
 In vitro, ketamine reduce inotropic effects as shown in chronically instrumented dogs 
which shows myocardial depression. However this is in contrast with another study 
involving isolated guinea pig hearts where ketamine was the least depressant of all the major 
induction drugs. This direct depressant effects of ketamine may be override by ketamine 
centrally mediated sympathetic responses. Stimulation of the cardiovascular system is not 
always advantageous to the patients, and some drugs have been used such adrenergic 
antagonists (a and ß), various vasodilators and clonidine to suppress these effects.  
 The most common method is administration of benzodiazepines prior to ketamine 
induction. Propofol and inhalation anaesthetics may also blunt the haemodynamic effect of 
ketamine. 
 
2.233 RESPIRATORY 
 
 Ketamine may cause transient decrease in minute ventilation after the bolus 
administration of an induction dose of ketamine (2 mg/kg intravenously). Overall effect on 
the central respiratory drive is minimal, as shown by an unaltered response to carbon 
dioxide. Arterial blood gases generally are preserved when ketamine is used alone for 
anaesthesia or analgesia. Apnoea may occur, but its incidence is rare if ketamine is used 
alone. However large doses of ketamine, or administration of adjuvant sedatives or 
anaesthetic drugs may result in respiratory depression.  
 Ketamine could improve pulmonary compliance and has a role as a bronchial smooth 
muscle relaxant. Ketamine has been used to treat asthmatic patient unresponsive to 
conventional therapy and sometimes given to patients with reactive airway disease and 
bronchospasm to improve compliance.  
 In children, ketamine may increases salivation that lead to upper airway obstruction, 
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and laryngospasm. Ketamine also may affect ventilatory control in children and should be 
considered a possible respiratory depressant when the drug is given to them in bolus doses. 
 
2.234 OTHER SIDE-EFFECTS 
 
 Ketamine is generally contraindicated for patients with increased ICP and with 
intracranial mass lesions because it can increase ICP and has been reported to cause apnoea. 
Ketamine also may be contraindicated in patients with an open eye injury or other 
ophthalmologic disorder, in which a ketamine-induced increase in intraocular pressure 
would be harmful.  
 Ketamine also not suitable to used as the sole anaesthetic in patients with ischaemic 
heart disease due to its susceptibility to cause hypertension and tachycardia and increase in 
myocardial oxygen consumption. Similarly patients with vascular aneurysms are contra 
indicated due to the potential sudden change in arterial pressure. 
 
2.24 USES 
 
2.241 INDUCTION AND MAINTENANCE OF ANAESTHESIA 
 
 Ketamine is an excellent choice for induction in patients with reactive airway disease 
due to its bronchodilation and analgesic action. Patients with haemodynamic compromise 
based on either hypovolaemia or cardiomyopathy, or trauma patient with large blood loss are 
candidates for rapid- sequence anaesthesia induction with ketamine. However intrinsic 
myocardial depressant effect of ketamine may manifest if trauma or sepsis has caused 
depletion of catecholamine stores before the patient's arrival in the operating room.  
 
Ketamine properties that preserves heart rate and right atrial pressure through its 
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sympathetic stimulation also makes it a good choice for patients with other cardiac diseases 
such as cardiac tamponade and restrictive pericarditis.  
 Patients with valvular and ischaemic heart disease may be given satisfactory cardiac 
anaesthesia by ketamine combined with propofol or midazolam infusion. Propofol with 
combination of low-dose ketamine has become more popular as a total IV anaesthesia 
technique for patients undergoing noncardiac surgery. The haemodynamic changes are 
minimal and slight ventilatory depression is noted when spontaneous ventilation is used. 
 
2.242 SEDATION 
 
 Ketamine has been used for sedation for many paediatric procedures such as cardiac 
catheterization, radiation therapy, radiologic studies, dressing changes and dental work. 
Usually it is combined with premedication of a barbiturate or benzodiazepine and an 
antisialagogue such as glycopyrrolate to facilitate procedures. Paediatric patients have fewer 
adverse emergence reactions compared to adult, and this put ketamine superior to other 
sedative agent. 
 Ketamine has also been used as an adjunct to regional anaesthesia. Procedures such as 
application of painful blocks or during long or uncomfortable procedures, IV ketamine (0.5 
mg/kg) can be given. Its combined sedative and analgesic properties and favourable effects 
on haemodynamics make ketamine a good choice as a sedation for patients in a critical care 
unit. 
 
2.243 PAIN MANAGEMENT 
 
 A few meta-analyses have showed an overall reduction in opiate use or improved 
analgesia and a decrease in opiate-induced side effects, especially incidence of post op 
nausea vomiting when ketamine given perioperatively. Ketamine combination with 
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morphine using an 8-minute lockout interval provided optimal postoperative analgesia in a 
mixture of 1:1 ratio. Another study involving total knee arthroplasty showed successful 
analgesia with an initial bolus of 0.5 mg/kg of ketamine followed by a continuous infusion 
of 3 μg/kg/min during surgery and 1.5 μg/kg/min for 48 hours after surgery.  
 Ketamine direct analgesic activity and its action on opiate tolerance and hyperalgesia 
have made ketamine becoming more popular in chronic pain states. Few trials have shown 
ketamine effectiveness in the treatment of cancer pain, chronic peripheral and central 
neuropathic pain, phantom and ischaemic limb pain, fibromyalgia, complex regional pain 
syndrome, visceral pain, and migraine. 
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2.3 FENTANYL  
 
2.31 CHEMISTRYAND FORMULATIONS 
 
Fentanyl is a synthetic opioid related to the phenylpiperidines. Due to its short time 
to peak analgesic effect, rapid offset of effect after small bolus doses, and favourable 
cardiovascular profile, fentanyl has become a popular anaesthetic agent. Dose of fentanyl 
depends on factors such as age, body weight, physical status, underlying pathological 
condition, use of other medicines, type of anaesthesia to be used, and the surgical procedure 
involved. In general dosage should be individualized. Elderly and sick patients usually need 
lower initial dose. Fentanyl can be given as a slow intravenous infusion or by patient-
controlled infusion device. An infusion may be started during surgery as an adjunct to 
general anaesthesia with a dose of 100 µg, increased as required until the desired effect is 
achieved. Epidural and intrathecal infusions, with or without local anaesthetic, are used in 
the management of chronic malignant pain and selected cases of nonmalignant pain. 
Sustained release of fentanyl for 48 hours or more are available as transdermal patches. 
 
2.33 PHARMACOKINETICS AND METABOLISM 
 
Fentanyl is most commonly administered intravenously, and it is 100 times more 
potent than morphine. Fentanyl is more lipid soluble than morphine, result in less risk of 
delayed respiratory depression from rostral spread of opioid given intrathecally. Fentanyl 
reach peak effect after 5 minutes compared to morphine which reach peak effect after 15 
minutes with faster recovery, as well. Prolonged infusion will prolong the drug effect with 
similar duration with other longer-acting opioids.  
Fentanyl decreases the heart rate and blood pressure mildly, and in general provides 
cardiovascular stability. Fentanyl is usually used for cardiovascular surgery or for patients 
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with poor cardiac function due to this property. Since fentanyl undergo hepatic metabolism 
and renal excretion, prolonged infusions result in longer duration of action.  
 With a single I.V. dose of fentanyl 100 micrograms, the usual duration of action of 
analgesic effect is 30 to 60 minutes. The duration of the respiratory depressant effect of 
fentanyl may be longer than the analgesic effect. Following administration of fentanyl, 
reduced sensitivity to CO2 stimulation may persist longer than depression of respiratory rate. 
Altered sensitivity to CO2 stimulation has been showed for up to four hours after a single IV 
dose of 600 micrograms fentanyl to healthy volunteers. In general the length of time and 
degree of respiratory depression is dose-dependent. Diaphragm rigidity can be solved by 
neuromuscular blocking agent. Fentanyl is metabolized in the liver, by cytochrome P450 
3A4 (CYP 3A4) to norfentanyl via oxidative N-dealkylation. 
 
2.34 SIDE EFFECTS 
 
 Fentanyl may result in bradycardia and asystole if fentanyl is combined with non-
vagolytic muscle relaxants. Bradycardia may be reversed with atropine. Suitable measures to 
keep a stable blood pressure should be taken because fentanyl may induce hypotension, 
especially in hypovolaemic patients.  
 The other actions of fentanyl such as euphoria, miosis, analgesia, bradycardia, 
bronchoconstriction, muscle rigidity and suppression of cough reflexes can be treated by 
specific antagonists, i.e. naloxone.  
 Changes in respiratory system which includes respiratory rate, alveolar ventilation are 
usually longer than the analgesic effect. The reduction in pulmonary exchange becomes 
greater with higher narcotic dose and may lead to apnoea in higher dose.  
 Histamine release rarely occurs with fentanyl, as shown in studies involving histamine 
assays and skin wheal testing in man. Higher doses of fentanyl, between 100-400 
micrograms/kg, cause a rapid reduction in blood pressure, which may last up to 30 minutes.  
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Like morphine, fentanyl has the potential to be abused due to its drug dependence. Chronic 
pain patients may require higher doses of opioid. Muscle rigidity caused by fentanyl is 
related to the speed of injection. It can be avoided by slow intravenous injection, muscle 
relaxants or premedication with benzodiazapines.  
 
2.4 SUPRAGLOTTIC AIRWAY DEVICES 
  
Supraglottic Airway Devices are designed to form a seal in the pharynx between the 
respiratory and digestive tracts to protect the airway and facilitate gas exchange. They are 
inserted blindly and the proximal tube will be connected to an anaesthesia circuit or other 
device. A better seal can be achieved with larger LMA, but this may increase the risk of 
sorethroat. There are several insertion techniques with gentleness is very important aspect of 
it. The “sniff” position is recommended for insertion of an LMA. Techniques developed 
over many years by Archie Brain may not be succesful in all patients and different 
techniques are sometimes needed to insert it.  
 Many drugs have been tested for LMA insertion with propofol or sevoflurane is 
considered the most favourable agent used. Opioids such as fentanyl, alfentanil may 
suppresses swallowing, coughing, gagging, and improve the ease of insertion and airway 
patency.  
 A sufficient depth of anaesthesia must be achieved before LMA insertion. LMA will 
be pushed along the palate and then the posterior pharyngeal wall until resistance increases 
which may indicates the tip lie within the upper oesophageal sphincter. Jaw thrust or direct 
laryngoscopy may be used to aid placing. Air is inflated into the cuff with cuff pressure not 
higher than 60 cm H2O. Too high pressure may reduce its effectiveness. After connected to 
the anaesthesia circuit, gentle manual ventilation will be carried out. Lung expansion is 
observed. Features of airway obstruction such as slow refill of the reservoir bag or detect 
sounds of respiratory obstruction from auscultation must be checked before proceed with 
